Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.
Video Library
Search the Video Library
Video Language
Filter by Cancer Type:
Displaying Results 1 - 15 of 43
UCLA Med Center's Dr. Eddie Garon discusses the open question of the optimal duration of ongoing treatment with immunotherapy for lung cancer.
Dr. Eddie Garon considers the data on immunotherapies for first line treatment of advanced NSCLC and whether we are likely to use these agents instead of or in combination with standard chemotherapy soon.
Stephen Liu, MD provides updates to our Lung Cancer Video Library. In this recent video, Dr. Liu discusses Continuing Immunotherapy Beyond Progression-In Which Patients Is This Appropriate
Lung Cancer Video Library 2018
Dr. H. Jack West, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, President and CEO of GRACE offers updates to our Lung Cancer Video Library. In this video, Dr. West discusses whether immunotherapy works in patients with driver mutations like EGFR and ALK. We thank the
Lung Cancer Video Library 2018
Dr. H. Jack West, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, President and CEO of GRACE offers updates to our Lung Cancer Video Library. In this video, Dr. West discusses chemotherapy and immunotherapy combinations in advanced squamous non-small cell lung cancer. We thank
Dr. Luis Raez, MD FACP FCCP, Chief of Hematology/Oncology and Med. Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at FL International University joined GRACE to discuss immune checkpoint inhibitors and how they can treat cancer.
Dr. Luis Raez, MD FACP FCCP, Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University joined GRACE to discuss second-line therapies for advanced NSCLC.
Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International U. joined GRACE to discuss integrating immune checkpoint inhibitors into first-line therapy for advanced NSCLC.
Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International U. joined GRACE to discuss potential side effects of immune checkpoint inhibitors and basic management approaches.
Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International U. joined GRACE to discuss biomarkers for predicting activity of immune checkpoint inhibitors.
Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, & Clinical Associate Prof. of Medicine at FL International University joined GRACE to discuss the response time on checkpoint inhibitors and the concept of pseudoprogression.
Jack West, MD, President and CEO of GRACE provides updates to our Lung Cancer Video Library. In this recent video, Dr. West discusses if immunotherapy should stop in responding patients after a fixed duration of treatment.
Nathan Pennell, MD, PhD, Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses the role for immunotherapy in patients with a driver mutation.
Dr. Luis Raez, MD FACP FCCP joined GRACE to discuss combinations for first-line treatment - immunotherapy with chemotherapy.